Skip to main content

IAVI 004

Phase:
I
Status:
Completed
Strategies:
Viral Vector - Pox
Candidates:
MVA.HIVA
Countries:
Kenya
Volunteers:
18
Partners:
Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya.

 

Study Summary:

This is a double-blind, randomized, placebo-controlled trial to evaluate an MVA vector-based HIV-1 clade A candidate vaccine, MVA.HIVA, in HIV-uninfected, healthy Kenyan male and female volunteers at low risk for HIV infection. This trial constitutes the second step in the development of a DNA vaccine for use in prime-boost regimens. Volunteers will be screened up to 4 weeks before entry, will receive two doses of 5 x 10^7 pfu MVA.HIVA intradermally at 4 week intervals, and will be followed up for 189 days after the first immunization. Additional follow-up visits at 12 and 18 months after the first immunization will be scheduled.